AI-powered sensorsenhance public safety, mitigating on-campus danger through real-time alertsIveda® (NASDAQ:IVDA), the global solution for cloud-based AI, today unveils the launch of IvedaAI Sense, an AI-based

IVDA

Proxy Advisory Firm ISS Recommends Bed Bath & Beyond Inc. Shareholders Vote “FOR” All Company Proposals; ISS Supports Approval Of Reverse Stock Split

By Happy Mohamed

April 11, 8:51 AM

ISS Supports Approval of Reverse Stock Split UNION, N.J., April 11, 2023 /PRNewswire/ -- Bed Bath & Beyond Inc. (NASDAQ:BBBY) (the "Company" or "BBBY") today announced that

BBBY

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan

By Benzinga Newsdesk

November 13, 7:01 AM

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the

AUPH

Chardan Capital Downgrades Vascular Biogenics to Neutral

Related Posts

JP Morgan Maintains Overweight on Signature Bank, Lowers Price Target to $135

Iveda Announces Launch of IvedaAI Sense With Cerebro AI Platform; IvedaAI Sense Has A Suggested Retail Price Of $1,500 Per Unit At Its Standard Configuration, With School Campus Requirements Anticipated To Range From 40–200 Units Depending On The Size…

Proxy Advisory Firm ISS Recommends Bed Bath & Beyond Inc. Shareholders Vote “FOR” All Company Proposals; ISS Supports Approval Of Reverse Stock Split

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS (Voclosporin) in Japan